SG11202004128TA - Acid-mediated assay for analyzing ligand-drug conjugates - Google Patents

Acid-mediated assay for analyzing ligand-drug conjugates

Info

Publication number
SG11202004128TA
SG11202004128TA SG11202004128TA SG11202004128TA SG11202004128TA SG 11202004128T A SG11202004128T A SG 11202004128TA SG 11202004128T A SG11202004128T A SG 11202004128TA SG 11202004128T A SG11202004128T A SG 11202004128TA SG 11202004128T A SG11202004128T A SG 11202004128TA
Authority
SG
Singapore
Prior art keywords
acid
drug conjugates
mediated assay
ligand
analyzing
Prior art date
Application number
SG11202004128TA
Other languages
English (en)
Inventor
Stephen Alley
Russell Sanderson
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of SG11202004128TA publication Critical patent/SG11202004128TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N30/06—Preparation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N2030/042—Standards
    • G01N2030/045—Standards internal
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N30/06—Preparation
    • G01N2030/067—Preparation by reaction, e.g. derivatising the sample
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG11202004128TA 2017-11-22 2018-11-20 Acid-mediated assay for analyzing ligand-drug conjugates SG11202004128TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762590169P 2017-11-22 2017-11-22
PCT/US2018/062100 WO2019104084A1 (fr) 2017-11-22 2018-11-20 Dosage à médiation par acide pour l'analyse de conjugués ligand-médicament

Publications (1)

Publication Number Publication Date
SG11202004128TA true SG11202004128TA (en) 2020-06-29

Family

ID=66632149

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004128TA SG11202004128TA (en) 2017-11-22 2018-11-20 Acid-mediated assay for analyzing ligand-drug conjugates

Country Status (11)

Country Link
US (1) US20200363425A1 (fr)
EP (1) EP3713588A4 (fr)
JP (1) JP2021504695A (fr)
KR (1) KR20200090195A (fr)
CN (1) CN111344001A (fr)
AU (1) AU2018370859A1 (fr)
CA (1) CA3082549A1 (fr)
IL (1) IL274656A (fr)
MX (1) MX2020005319A (fr)
SG (1) SG11202004128TA (fr)
WO (1) WO2019104084A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230022980A1 (en) * 2019-09-04 2023-01-26 Seagen Inc. Double-digestion assay for analyzing ligand-drug conjugates
US11930499B2 (en) * 2021-04-07 2024-03-12 Tencent America LLC Network monitoring in service enabler architecture layer (SEAL)
CN114646719A (zh) * 2022-04-08 2022-06-21 宁波熙宁检测技术有限公司 一种血浆中mmae的液质联用检测方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0683676A4 (fr) * 1993-02-02 1998-09-30 Neorx Corp Biodistribution dirigee des petites molecules.
US7659241B2 (en) * 2002-07-31 2010-02-09 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
EP2208992A1 (fr) * 2003-11-21 2010-07-21 Eisai R&D Management Co., Ltd. Procédé de quantification faisant intervenir un étalon interne marqué par un isotope, système d'analyse pour exécution du procédé de quantification et programme de séparation associé
EP2121667B1 (fr) * 2007-02-21 2016-06-08 E. R. Squibb & Sons, L.L.C. Liants chimiques avec acides aminés uniques et conjugués de ceux-ci
GB201213127D0 (en) * 2012-07-24 2012-09-05 Univ Dundee Novel isotopic labelling method
WO2014197754A1 (fr) * 2013-06-07 2014-12-11 Pierce Biotechnology, Inc. Quantification absolue de protéines et de modifications de protéines par spectrométrie de masse à étalons internes multiplexés
EA201690780A1 (ru) * 2013-10-15 2016-08-31 Сиэтл Дженетикс, Инк. Пегилированные лекарственные средства-линкеры для улучшенной фармакокинетики конъюгатов лиганд-лекарственное средство
US9594085B2 (en) * 2014-02-03 2017-03-14 Integrated Diagnostics, Inc. Integrated quantification method for protein measurements in clinical proteomics
TWI618697B (zh) * 2015-11-03 2018-03-21 財團法人工業技術研究院 化合物、連接子－藥物、及配體－藥物耦合體
JP6943872B2 (ja) * 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ

Also Published As

Publication number Publication date
EP3713588A1 (fr) 2020-09-30
WO2019104084A1 (fr) 2019-05-31
CA3082549A1 (fr) 2019-05-31
JP2021504695A (ja) 2021-02-15
KR20200090195A (ko) 2020-07-28
EP3713588A4 (fr) 2021-08-04
US20200363425A1 (en) 2020-11-19
MX2020005319A (es) 2020-10-01
AU2018370859A1 (en) 2020-06-18
CN111344001A (zh) 2020-06-26
IL274656A (en) 2020-06-30

Similar Documents

Publication Publication Date Title
HK1258539A1 (zh) 微瞬間分析
GB2554180B (en) Spectrometric analysis
EP3372985A4 (fr) Dispositif d'analyse
IL259531B (en) Test facility
GB2602212B (en) Spectrometric analysis
GB201611840D0 (en) Alpha-synuclein detection assay
PL3336514T3 (pl) Próbnik do analizy bezpośredniej
SG10201601097XA (en) Amplitude-versus-angle analysis for quantitative interpretation
PL3336511T3 (pl) Urządzenie do pobierania próbek do bezpośredniej analizy
GB201710394D0 (en) Multicolour fluorescence analysis device
GB2551937B (en) Biopsy sample retention mechanism
IL266857A (en) You will notice antibodies
IL274656A (en) An acid-mediated assay for the analysis of ligand-drug conjugates
GB201514730D0 (en) Assay device
EP3428633A4 (fr) Dispositif d'analyse
GB2561879B (en) Spectroscopic analysis
EP3388830A4 (fr) Dispositif d'analyse
GB2570742B (en) Optical-interference analysis
EP3307712A4 (fr) Réactifs de bioconjugaison radio-iodés
GB2579810B (en) Assay Analysis
GB201614152D0 (en) Assay
GB201605288D0 (en) Analysis device
GB201605210D0 (en) Assay
GB201514712D0 (en) Assay device
GB2580271B (en) Analysis device